Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Molecular Therapy Oncolytics
|
April 28, 2016
Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity
Marie-Claude Bourgeois-Daigneault, Dominic Guy Roy, Theresa Falls, et al.
Science Translational Medicine
|
January 5, 2018
Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
Marie-Claude Bourgeois-Daigneault, Dominic Guy Roy, Amelia Sadie Aitken, et al.
Nucleic Acids Research
|
December 17, 2020
The mTOR regulated RNA-binding protein LARP1 requires PABPC1 for guided mRNA interaction
Ewan M Smith, Nour El Houda Benbahouche, Katherine Morris, et al.
International Health
|
January 9, 2025
Variability of interobserver interpretation of selected helminth ova in the development of a training image set
Rupert Stephen Charles S Chua, Kiersten A Henderson, Lorenzo Maria C de Guzman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
May 7, 2026
Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy
Mélissa Viens, Karen Geoffroy, Elline Meuriot, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie
|
September 15, 2020
Evaluation of a preoperative personalized risk communication tool: a prospective before-and-after study
Emily Hladkowicz, David Yachnin, Laura Boland, et al.
Plos Pathogens
|
August 24, 2018
Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis
Chadi Zakaria, Polen Sean, Huy-Dung Hoang, et al.
Frontiers in Immunology
|
November 21, 2022
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
Mathieu J F Crupi, Zaid Taha, Thijs J A Janssen, et al.
Nature Communications
|
August 23, 2024
Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy
Zaid Taha, Mathieu Joseph François Crupi, Nouf Alluqmani, et al.
Nature Communications
|
June 18, 2021
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Diana Zatreanu, Helen M R Robinson, Omar Alkhatib, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Molecular Therapy Oncolytics
|
April 28, 2016
Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity
Marie-Claude Bourgeois-Daigneault, Dominic Guy Roy, Theresa Falls, et al.
Science Translational Medicine
|
January 5, 2018
Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
Marie-Claude Bourgeois-Daigneault, Dominic Guy Roy, Amelia Sadie Aitken, et al.
Nucleic Acids Research
|
December 17, 2020
The mTOR regulated RNA-binding protein LARP1 requires PABPC1 for guided mRNA interaction
Ewan M Smith, Nour El Houda Benbahouche, Katherine Morris, et al.
International Health
|
January 9, 2025
Variability of interobserver interpretation of selected helminth ova in the development of a training image set
Rupert Stephen Charles S Chua, Kiersten A Henderson, Lorenzo Maria C de Guzman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
May 7, 2026
Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy
Mélissa Viens, Karen Geoffroy, Elline Meuriot, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie
|
September 15, 2020
Evaluation of a preoperative personalized risk communication tool: a prospective before-and-after study
Emily Hladkowicz, David Yachnin, Laura Boland, et al.
Plos Pathogens
|
August 24, 2018
Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis
Chadi Zakaria, Polen Sean, Huy-Dung Hoang, et al.
Frontiers in Immunology
|
November 21, 2022
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
Mathieu J F Crupi, Zaid Taha, Thijs J A Janssen, et al.
Nature Communications
|
August 23, 2024
Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy
Zaid Taha, Mathieu Joseph François Crupi, Nouf Alluqmani, et al.
Nature Communications
|
June 18, 2021
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Diana Zatreanu, Helen M R Robinson, Omar Alkhatib, et al.
Page
of 5